In Situ Detection and Quantification of AR-V7, AR-FL, PSA, and

El-Heliebi A, Hille C, Laxman N, Svedlund J, Haudum C, Ercan E, Kroneis T, Chen S, Smolle M, Rossmann C, Krzywkowski T, Ahlford A, Darai E, von Amsberg G, Alsdorf W, König F, Löhr M, de Kruijff I, Riethdorf S, Gorges TM, Pantel K, Bauernhofer T, Nilsson M, Sedlmayr P

Clin. Chem. 64 (3) 536-546 [2018-03-00; online 2018-01-04]

Liquid biopsies can be used in castration-resistant prostate cancer (CRPC) to detect androgen receptor splice variant 7 (AR-V7), a splicing product of the androgen receptor. Patients with AR-V7-positive circulating tumor cells (CTCs) have greater benefit of taxane chemotherapy compared with novel hormonal therapies, indicating a treatment-selection biomarker. Likewise, in those with pancreatic cancer (PaCa), We studied 3 independent CTC-isolation devices (CellCollector, Parsortix, CellSearch) for the evaluation of AR-V7 or KRAS status of CTCs with in situ padlock probe technology. Padlock probes allow highly specific detection and visualization of transcripts on a cellular level. We applied padlock probes for detecting AR-V7, androgen receptor full length (AR-FL), and prostate-specific antigen (PSA) in CRPC and In situ analysis showed that 71% (22 of 31) of CRPC patients had detectable AR-V7 expression ranging from low to high expression [1-76 rolling circle products (RCPs)/CTC]. In PaCa patients, 40% (6 of 15) had Padlock probe technology enables quantification of AR-V7, AR-FL, PSA, and

Affiliated researcher

PubMed 29301749

DOI 10.1373/clinchem.2017.281295

Crossref 10.1373/clinchem.2017.281295

pii: clinchem.2017.281295


Publications 9.5.0